[ad_1]
Vancouver, British Columbia and Rehovot, Israel – (Newsfile Corp. – February 12, 2024) – BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or ” Company”), a pioneer in phytosynthetic technologies that grow botanical active ingredients without growing plants, announced that it will participate in and sponsor the 2024 BIO CEO and Investor Conference, which will take place on February 26-27, 2024 held in New York City.
BioHarvest CEO Ilan Sobel plans to hold one-on-one meetings with accredited institutional investors throughout the conference. He will be joined by company chairman Zaki Rakib and chief medical officer Dr. Brian Cornblatt. In addition, Mr. Sobel plans to deliver the following presentations to attendees:
2024 Bio CEO and Investor Conference
date: Monday, February 26, 2024
time: 10:00 AM EST
Place: New York Marriott Marquis | 1535 Broadway, New York, NY
“The BIO CEO and Investor Conference is one of the largest and most prestigious global events for biotech investors, making it an ideal place for us to showcase our disruptive plant synthesis platform and upcoming 2024 growth catalysts,” said Ilan Sobel, CEO of BioHarvest. Forum.” “The strategic steps we have taken over the past twelve months put BioHarvest in a better position than ever to accelerate our rapid growth trajectory and drive long-term sustainable shareholder value. That said, I Looking forward to our upcoming presentation, which will showcase it to some of the most sophisticated investors and influencers in the industry.”
The company invites interested BIO CEO and investor meeting attendees to request to attend the meeting through the 1×1 system. Chief Executive Ilan Sobel and Chairman Zaki Rakib will host additional investor meetings outside of the conference. For more information or to request a meeting, please contact the company’s investor relations team at info@bioharvest.com.
About BIO CEO & Investor Conference
The BIO CEO and Investor Conference provides timely and relevant content on issues driving biotech business, as well as a valuable platform for networking and collaboration. The conference brings together biotech executives with the investment community to discover the latest innovations in biotech during company presentations and hear from thought leaders in sessions on therapeutic advances, market prospects and policy priorities. To learn more, visit the conference website: https://bcic.bio.org/.
For more information please contact:
BioHarvest Sciences Investor Relations
+1 (778) 686-3855
info@bioharvest.com
About BioHarvest Sciences, Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in plant synthesis, leveraging its patented technology platform to grow active ingredients in plants without the need to grow a base plant. BioHarvest is currently focused on leveraging its phytosynthetic technology to develop the next generation of scientifically based and clinically proven therapeutic solutions across two main business verticals – nutritional health and wellness products such as dietary supplements, and the development of plant cell-based active pharmaceuticals. Ingredients (APIs) for specific medical indications. To learn more, visit www.bioharvest.com.
forward-looking statements
Information set forth in this press release may include forward-looking statements that are based on management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ from those described herein. There are significant differences in the results. Forward-Looking Statements.
All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our periodic management discussions and analyses.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this release, please visit https://www.newsfilecorp.com/release/197589
[ad_2]
Source link